Ultramicronized Palmitoylethanolamide in the Management of Neuropathic Pain Related to Chronic Inflammatory Demyelinating Polyneuropathy: A Proof-of-Concept Study
Open-label, no control groupHumans
- Design
- Open-label, no control group
- Subjects
- 14 patients at one centre. All completed.
- Dose used in the study
- 600 mg of ultramicronised palmitoylethanolamide twice a day (Normast 600 tablets)
- Duration
- 60 days of treatment within 180 days of observation
- What was measured
- Pain intensity, the Neuropathic Pain Symptoms Inventory and a quality of life questionnaire
What the authors reported
The authors reported improvements in pain intensity (p = 0.0015), neuropathic pain symptoms (p = 0.0007) and quality of life (p = 0.0036) during treatment. They observed no adverse events related to the supplement.
Limits of this study
An open-label study with no placebo, 14 patients and one centre. The authors name these limits themselves. The study received no external funding.
Source
Entry checked against the full text at the publisher (MDPI) on 2026-09-21. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.